How Long Can a Person Live With MGUS?

Most people diagnosed with MGUS live for many years, and the majority never develop cancer from it. A large Swedish population study of over 4,200 patients found that five years after diagnosis, survival was 93% of what would be expected for people of the same age and sex in the general population, dropping to about 82% at ten years and 70% at fifteen years. That gap between MGUS patients and the general population is real but modest, and it comes from a mix of causes, not just the possibility of progression to myeloma. Understanding those causes, and where your individual risk sits, is what determines how to think about life with MGUS.

What the Survival Numbers Actually Show

The most informative way to measure how MGUS affects lifespan is through relative survival, which compares how long MGUS patients live against how long matched members of the general population live. A study following 4,259 Swedish MGUS patients found one-year relative survival of 0.98, meaning patients survived at 98% the rate of their peers during that first year. At five years it was 0.93, at ten years 0.82, and at fifteen years 0.70.¹ The shortfall grew with time and was steepest among older patients. Younger patients diagnosed with MGUS had significantly lower excess mortality compared to older ones.

Those numbers deserve context. A 15-year relative survival of 0.70 does not mean 30% of MGUS patients die within 15 years. It means their survival rate is about 70% of what you would expect for people the same age without MGUS. Since MGUS is overwhelmingly diagnosed in people over 50, many of those individuals are already at ages where overall mortality from heart disease, stroke, and other conditions is climbing. MGUS adds a measurable layer of risk on top of the background rate, but for most people it is not the dominant threat to their longevity.

The Progression Risk That Defines MGUS

The defining clinical feature of MGUS is a roughly 1% per year risk of progression to multiple myeloma or a related blood cancer such as Waldenström’s macroglobulinemia or AL amyloidosis.² That figure, established in a landmark study with decades of follow-up, has held up consistently. An international consensus statement confirmed the same estimate,³ and a recent systematic review pooling data from multiple studies found an overall progression rate of about 1.2% per year to any blood cancer and 0.8% per year specifically to myeloma.⁴

A critical point about that 1% per year figure: the risk does not go away over time. It persists indefinitely, which means the longer you live with MGUS, the higher your cumulative chance of eventually progressing. Someone who has had MGUS for 20 years faces a meaningful cumulative probability. But for any given individual in any given year, the odds strongly favor nothing happening.

What Makes Some Cases Riskier Than Others

That average 1% annual rate masks enormous variation between individuals. A long-term follow-up study from the Mayo Clinic tracked patients for up to 35 years and identified two key risk factors that predict progression: the level of the abnormal protein in the blood (M-protein) and the ratio of two types of light chains the immune system produces. Among patients with IgM-type MGUS who had both risk factors, the 20-year progression rate was 55%. For those with neither risk factor, it was 19%. In non-IgM MGUS, the contrast was between 30% progression at 20 years for those with both risk factors and just 7% for those with none.⁵

These numbers illustrate why individual risk assessment matters far more than the average. A person with low-risk MGUS, characterized by a small M-protein level and a normal light-chain ratio, has a very different outlook than someone with high-risk features. Beyond those two markers, progression risk is shaped by other factors including the type of abnormal protein involved, bone marrow characteristics, and cytogenetic abnormalities in the underlying clone of cells.⁶⁷

Why MGUS Shortens Lifespan Even Without Cancer

Here is something that surprises many people after diagnosis: the excess mortality among MGUS patients is not entirely, or even mostly, explained by progression to myeloma. A study of over 1,700 MGUS patients in southeastern Minnesota found that malignant transformation accounted for only about 20% of the excess deaths in the cohort. The rest came from a range of other malignant and non-malignant causes, particularly in the first few years after MGUS was detected.⁸

Why would MGUS be associated with dying from conditions that seem unrelated to blood cancer? Part of the answer is likely confounding: MGUS is often discovered incidentally during workups for other medical problems, so the people in whom it gets detected may already be sicker than average. But there also appear to be direct biological connections. The abnormal protein and the immune environment it reflects can affect multiple organ systems in ways that do not amount to cancer but still carry consequences. This is especially clear for two areas: the kidneys and the bones.

When the Kidneys Are Involved

A subset of MGUS cases cause damage to the kidneys even though they never progress to full-blown myeloma. This has been recognized as a distinct clinical entity called monoclonal gammopathy of renal significance, or MGRS. The name was created specifically to separate these patients from the broader, lower-risk MGUS category, because the kidney involvement carries its own serious consequences including the potential for chronic kidney disease.⁹

Patients with MGRS also face a higher risk of eventually progressing to myeloma. In a study of nearly 3,000 MGUS patients, those with kidney involvement progressed at a rate of about 18%, compared to 3% for standard MGUS patients. The hazard ratio for progression was 3.3, and the risk within the first year alone was roughly ten times higher for MGRS patients.¹⁰ MGRS is one reason why a diagnosis that sounds benign can sometimes demand active treatment rather than just monitoring.

Bone Health and Fracture Risk

Myeloma is well known for causing bone destruction, but MGUS may also affect the skeleton in subtler ways. There is growing evidence that MGUS is linked to increased fracture risk, and that MGUS turns up more often than expected in people being evaluated for osteoporosis.¹¹ The mechanism appears to be different from typical osteoporosis, though. A population-based screening study in Iceland found that people with MGUS did not have lower bone mineral density than those without it. In fact, they had higher bone volume. Yet men with MGUS still had about a 50% increased fracture risk compared to other men.¹²

This paradox, higher bone volume but more fractures, suggests that the abnormal protein or the immune cells producing it may compromise bone quality in ways that standard density scans do not capture. For patients and their doctors, it means that a fracture in someone with MGUS should not be dismissed as simple aging or garden-variety osteoporosis without considering whether the underlying gammopathy is playing a role.

Blood Clot Risk

MGUS is also associated with an increased risk of deep vein thrombosis. One study found that the overall incidence of blood clots was about 3.1 per 1,000 person-years in MGUS patients, translating to roughly a threefold increase compared to the general population. The risk was highest in the first year after diagnosis, when MGUS patients had about an eightfold relative risk of clotting.¹³ This elevated early risk likely reflects both the biology of the condition and the fact that new diagnoses often occur during medical workups when patients are already unwell. Still, it is worth being aware of, and any symptoms that suggest a blood clot deserve prompt attention.

Does Age at Diagnosis Change the Picture?

MGUS is overwhelmingly a condition of older adults. In predominantly white populations, about 3.2% of people over 50 carry MGUS,¹⁴ and prevalence climbs steeply with age. The Icelandic screening study found rates of 2.3% in people aged 40 to 59, 6.2% in those 60 to 79, and 12.9% in people 80 and older.¹⁵ The condition is also more common in men than women and substantially more common in Black individuals, with adjusted prevalence roughly 60% to over twice as high as in white populations.¹⁶

Young adults under 40 can get MGUS, but it is rare, with a prevalence below 0.3%. A study of 249 such patients found that their annual progression risk was essentially the same as in older patients, about 1.4% per year, with cumulative progression reaching about 6% at five years and nearly 14% at ten years.¹⁷ Because younger patients have decades of remaining life expectancy during which that annual risk accumulates, the lifetime probability of eventually developing a related cancer is higher for them even though their annual risk is not. Younger patients also tend to tolerate the treatments for myeloma better if progression does occur, which somewhat offsets the longer time horizon.

How MGUS Is Monitored

There is no treatment for MGUS itself. The standard approach is watchful waiting with regular blood tests. A 2024 review in JAMA Internal Medicine laid out the current consensus: patients with low-risk MGUS can safely skip bone marrow biopsy and advanced imaging, relying on periodic lab work instead. Those with intermediate- or high-risk features should undergo more thorough initial evaluation and shorter monitoring intervals.¹⁸

In practice, monitoring typically involves blood tests every six to twelve months, including measures of the abnormal protein level, blood counts, and kidney function. This continues indefinitely, because the risk of progression never fully goes away.¹⁹ The goal is to catch any signs of progression early, when treatment for myeloma is most effective. If your numbers remain stable over several years, that is reassuring, but it does not mean monitoring can stop.

The Emotional Weight of a “Pre-Cancer” Label

Doctors sometimes describe MGUS as a “pre-malignant” condition, and while that is technically accurate, the label can carry a psychological cost that is often underestimated. A study of patients with MGUS and its close relative, smoldering myeloma, found that about 22% of MGUS patients reported clinically meaningful anxiety, and a third had a previous psychiatric disorder.²⁰

A separate mixed-methods study painted an even more detailed picture. Patients described the experience of living with MGUS as carrying an internal “time bomb,” with anxiety levels that were significantly higher than general population norms. Fatigue, disrupted sleep, and reduced participation in social activities were also elevated. Some patients approached what researchers classified as severe anxiety.²¹ The monitoring itself can feed the cycle: the regular blood draws become a recurring source of dread rather than reassurance. If you recognize this pattern in yourself, it is worth raising with your doctor. The anxiety is common, it is not a sign of weakness, and there are ways to manage it.

Lifestyle Factors and Emerging Research

Because MGUS cannot currently be treated or cured, an active area of research asks whether lifestyle factors might influence the risk of developing it or progressing from it. A study of a high-risk population found that obesity was associated with a 73% higher odds of having MGUS detected by sensitive mass spectrometry testing. Heavy smoking, defined as more than 30 pack-years, roughly doubled the odds. On the protective side, high levels of physical activity were linked to about half the odds of MGUS, and sleeping fewer than six hours per night was associated with about double the odds.²²

Whether modifying these factors after an MGUS diagnosis actually prevents progression remains unproven. The epidemiological link between obesity and blood cancers is supported by multiple studies, but confounders like diet and physical activity make it hard to isolate the effect of weight alone.²³ Still, maintaining a healthy weight, staying physically active, and not smoking are defensible advice for people with MGUS, if only because they protect against the many other causes of death that contribute to the excess mortality in MGUS patients.

Family History and Genetic Predisposition

MGUS and myeloma run in families to some degree. First-degree relatives of myeloma patients have an estimated two- to fourfold increased risk of developing myeloma themselves, along with elevated rates of MGUS and other blood cancers.²⁴ This does not mean MGUS is inherited in any straightforward way, but if you have a parent or sibling with myeloma, your baseline risk of carrying MGUS is higher than the population average, and earlier screening may be warranted.

How Newer Testing Is Changing the Landscape

The traditional method for detecting the abnormal protein in MGUS, gel-based electrophoresis, misses very small amounts. Mass spectrometry can pick up M-proteins well below the detection threshold of older tests, leading researchers to define a new category called monoclonal gammopathy of indeterminate potential, or MGIP, for these very low-level findings.²⁵ Whether MGIP carries the same clinical implications as traditional MGUS, or whether it represents something even more benign, is still being worked out.

The iStopMM study in Iceland, which screened over 75,000 participants for MGUS, is the first population-based effort to determine whether screening everyone for MGUS and then following them systematically improves outcomes.²⁶ Among those screened, 4.9% had MGUS, with prevalence reaching nearly 13% in people over 80.¹⁵ The study is randomizing newly detected MGUS patients to different monitoring strategies to determine whether earlier and more intensive follow-up actually prevents advanced myeloma or merely detects it sooner without changing outcomes. The results could reshape how we think about MGUS screening in the general population, but for now, routine screening is not recommended outside of research settings or high-risk families.